Table 3 Multivariable analyses in validation ER-positive cohorts
From: Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer
Cohort | Covariates | Recurrence-free survival | |
|---|---|---|---|
HR (95% CI) | P | ||
E-MTAB-365 ER-positive cohorta | |||
|  | FFAR4 (continuous) | 1.168 (0.988–1.381) | 0.070 |
|  | Age at diagnosis | 1.015 (0.995–1.037) | 0.149 |
|  | Grade (3 vs 2 or 1) | 1.656 (0.995–2.756) | 0.052 |
|  | LN (positive vs negative) | 1.687 (0.986–2.888) | 0.056 |
|  | FFAR4 (high vs low) | 1.512 (0.944–2.421) | 0.086 |
|  | Age at diagnosis | 1.014 (0.993–1.035) | 0.183 |
|  | Grade (3 vs 2 or 1) | 1.660 (0.998–2.759) | 0.051 |
|  | LN (positive vs negative) | 1.659 (0.968–2.843) | 0.066 |
GSE4922 ER-positive cohort | |||
|  | FFAR4 (continuous) | 1.236 (1.017–1.507) | 0.033 |
|  | Age at diagnosis | 1.003 (0.985–1.021) | 0.723 |
|  | Grade (3 vs 2 or 1) | 1.404 (0.792–2.489) | 0.245 |
|  | Tumor size (> 2 cm vs ≤ 2 cm) | 2.215 (1.349–3.639) | 0.002 |
|  | LN (positive vs negative) | 1.542 (0.945–2.517) | 0.083 |
|  | FFAR4 (high vs low) | 1.738 (1.068–2.828) | 0.026 |
|  | Age at diagnosis | 1.002 (0.984–1.020) | 0.834 |
|  | Grade (3 vs 2 or 1) | 1.308 (0.728–2.350) | 0.370 |
|  | Tumor size (> 2 cm vs ≤ 2 cm) | 2.213 (1.347–3.635) | 0.002 |
|  | LN (positive vs negative) | 1.551 (0.952–2.527) | 0.078 |